null

null

null

null

null

null

null

null

null

0.02x Total Debt / Equity (Conservative)

Low sensitivity; RTI carries minimal long-term debt (~$10M), so a 200bps rate rise adds negligible interest expense, under $200K annually

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

Chinese resin/polymer suppliers and Malaysian/Southeast Asian component manufacturers are top chokepoints for needle and barrel inputs

International revenue ~15-20% of total; primary exposure in Europe (EUR), Latin America (BRL/MXN), and Middle East (USD-pegged), moderate devaluation risk

Primarily USD-denominated domestic revenue (~80%); EUR and BRL exposure modest; sovereign devaluation risk manageable but limits international margin predictability

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

Single resin/polymer supplier concentration is meaningful risk; proprietary needle retraction mechanism components sourced from limited vendors, likely >30% input cost share

Minimal cloud infrastructure dependency; RTI operates manufacturing-centric model; cloud account termination would affect back-office/ERP systems only, not core production

Secondary digital operations (order management, logistics software) could face 30-60 day disruption but core manufacturing would be unaffected by cloud termination

Negligible API coupling risk; RTI is a medical device manufacturer with minimal SaaS/API dependencies; operational software is largely on-premise or commodity ERP

No Howey Test risk; RTI sells physical medical devices (safety syringes) under standard commercial contracts; no investment-contract characteristics present

Very High

Low GDPR/CCPA exposure; RTI handles limited personal data (B2B customer contacts, employee records); no patient data processed directly; compliance burden is moderate-standard

Moderate historical antitrust risk; RTI has previously litigated against BD and others for anticompetitive GPO contracting; as challenger, not dominant player, exposure is low

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Predominantly transactional (~90%+); revenue driven by per-unit device sales to hospitals and distributors; multi-year GPO contracts provide some visibility but aren't subscription-based

Per-unit product sales through distributors and direct hospital/government channels; no meaningful recurring subscription or service revenue stream identified

Pricing constrained by GPO contract ceilings and competitive bidding; limited ability to pass through raw material cost increases; margin compression risk under commodity inflation

Low-to-moderate; safety syringe market is commoditized; pricing largely determined by GPO negotiations; RTI competes on safety feature differentiation but faces BD price pressure

0.1% Gross Margin (Thin (<20%))

No free-rider problem; products are consumable physical goods with no digital commons; customer churn risk tied to GPO contract renewals and competitive bids every 3-5 years

Revenue growth is roughly headcount-linear due to manufacturing model; doubling output requires proportional production workers; limited operating leverage vs. software peers

Marginal cost of growth is high relative to software; each incremental unit requires materials, labor, and capital equipment; gross margins ~35-45%, improving modestly at scale

Not applicable; RTI operates as a direct manufacturer, not a franchise network

At 10x scale, GPO contracting remains primary channel; CAC stays low but GPO pricing concessions intensify; unit economics likely improve modestly through manufacturing leverage

No meaningful network effects; medical device consumables market lacks network externalities; adoption driven by clinical efficacy, safety mandates, and procurement contracts

-8.6% Return on Assets (Negative equity)

Tier 1 recession resistant; safety syringes are non-discretionary medical consumables; hospital procurement volumes relatively stable through economic downturns

Hospitals, integrated delivery networks, and government health agencies; GPO-affiliated acute care facilities represent majority of volume; high concentration in top 5 GPOs

Government and military procurement (VA, DoD) and international public health organizations (WHO, PAHO); provides revenue diversification but adds procurement cycle complexity

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

3.8% CapEx / Revenue (Low-CapEx Asset-Light)

0000946563

RVP